Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 422-425

  Dong, Yan ^a   Steffen, Brian T ^a   Cao, Jing ^a   Tsai, Alexander K ^a   Ordovas, Jose ^b   Straka, Robert ^c   Zhou, Xia ^c   Kabagambe, Edmond ^d   Hanson, Naomi Q ^a   Arnett, Donna ^d   Tsai, Michael Y ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Atherosclerosis; Fenofibrate; GOLDN; Isoprostane; Ox LDL; Triglyceride

Indexed keywords

8 ISOPROSTANE; FENOFIBRATE; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; DRUG EFFECT; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; COHORT STUDIES; DINOPROST; FENOFIBRATE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; OXIDATIVE STRESS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 79151482401     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.022     Document Type: Article

References (22)

1. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007, 67:121-153.
2. Birjmohun R.S., Hutten B.A., Kastelein J.J., Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197.
3. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591.
4. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
5. Fruchart J.C., Sacks F.M., Hermans M.P. Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin 2010, 26(8):1793-1797.
6. Nishi K., Itabe H., Uno M., et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002, 22:1649-1654.
7. Pratico D., Iuliano L., Mauriello A., et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997, 100:2028-2034.
8. Vassalle C., Botto N., Andreassi M.G., Berti S., Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003, 14:213-218.
9. Verhoye E., Langlois M.R. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?. Clin Chem Lab Med 2009, 47:128-137.
10. Wang B., Pan J., Wang L., Zhu H., Yu R., Zou Y. Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis 2006, 184:425-430.
11. Daub K., Seizer P., Stellos K., et al. Oxidized LDL-activated platelets induce vascular inflammation. Semin Thromb Hemost 2010, 36:146-156.
12. Khan B.V., Parthasarathy S.S., Alexander R.W., Medford R.M. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995, 95:1262-1270.
13. Lehr H.A., Olofsson A.M., Carew T.E., et al. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994, 71:380-386.
14. Fan J., Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003, 10:63-71.
15. De Caterina R., Cipollone F., Filardo F.P., et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 2002, 106:2543-2549.
16. Desideri G., Croce G., Tucci M., et al. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab 2003, 88:5341-5347.
17. Lai C.Q., Arnett D.K., Corella D., et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol 2007, 27:1417-1425.
18. Holtzman J.L. The Role of Glutathione Pathways in the Prevention of Atherosclerosis, in Atherosclerosis and Oxidant Stress 2008, Springer, USA, p. 211-226.
19. Tkac I., Molcanyiova A., Javorsky M., Kozarova M. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol Res 2006, 53:261-264.
20. Phuntuwate W., Suthisisang C., Koanantakul B., Chaloeiphap P., Mackness B., Mackness M. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 2008, 196:122-128.
21. Hodgson J.M., Watts G.F., Playford D.A., Burke V., Croft K.D. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002, 56:1137-1142.
22. Hogue J.C., Lamarche B., Tremblay A.J., Bergeron J., Gagné C., Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008, 57(March (3)):380-386.